Search Result

Isoforms Recommended:	HIF

Results for "

HIF2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) HIF/HIF Prolyl-Hydroxylase (35) MMP (1) Ras (1) Xanthine Oxidase (3)
By Research Areas:	Cancer (35) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (9) Metabolic Disease (3) Neurological Disease (3)
Oligonucleotides:	siRNAs (2)

Inhibitors & Agonists

Peptides

Natural
Products

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148860

HIF-2α-IN-8	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-8 is a potent and orally active *HIF2α* inhibitor with IC₅₀ values of 9, 37, 246 nM for HIF2α SPA, HIF2α iScript, HIF2α HRE RGA, respectively. HIF-2α-IN-8 shows antitumor activity .

HY-136748

HIF-2α-IN-4 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-4 is a potent inhibitor of hypoxia inducible factor-2α (HIF-2α) translation, with an IC₅₀ of 5 μM. HIF-2α-IN-4 decreases both constitutive and hypoxia-induced HIF-2α protein expression. HIF-2α-IN-4 links its 5'UTR iron-responsive element to oxygen sensing .

HY-19949

HIF-2α-IN-1 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
HIF-2α-IN-1 is a HIF-2α inhibitor with an IC50 value of less than 500 nM.

HY-144178

HIF-2α-IN-6	HIF/HIF Prolyl-Hydroxylase	Others
HIF-2α-IN-6 (117) is a *HIF-2α* inhibitor .

HY-144176

HIF-2α-IN-5	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-5 is a potent *HIF-2α* inhibitor with an IC₅₀ of < 50 nM .

HY-163598

HIF-2α-IN-11	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-11 (1) is a *HIF-2α* inhibitor, with an IC₅₀ of 59.2 nM .

HY-163597

HIF-2α-IN-10	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-10 (17) is a *HIF-2α* inhibitor, with an IC₅₀ of 0.05 μM .

HY-163599

HIF-2α-IN-12	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-12 (9) is a *HIF-2α* inhibitor, with an IC₅₀ of 0.9 μM .

HY-163600

HIF-2α-IN-13	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-13 (18) is a *HIF-2α* inhibitor, with an IC₅₀ of 2.7 μM .

HY-163601

HIF-2α-IN-14	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-14 (18) is a *HIF-2α* inhibitor, with an IC₅₀ of 0.27 μM .

HY-163602

HIF-2α-IN-15	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-15 (35) is a *HIF-2α* inhibitor, with an IC₅₀ of 0.41 μM .

HY-163603

HIF-2α-IN-16	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-16 (48) is a *HIF-2α* inhibitor, with an IC₅₀ of 0.091 μM .

HY-18370

HIF-2α-IN-3	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α (HIF-2α), exhibits an IC₅₀ of 0.4 µM and a K_D of 1.1 µM. Anticancer agent .

HY-130264

HIF-2α-IN-2	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC₅₀ of 16 nM in scintillation proximity assay (SPA) .

HY-148264

Imdatifan HIF-2α-IN-7	HIF/HIF Prolyl-Hydroxylase	Infection Metabolic Disease Inflammation/Immunology Cancer
Imdatifan (HIF-2α-IN-7) is a hypoxia inducible factor 2α (HIF-2α) inhibitor. Imdatifan can inhibit HIF-2α with an EC₅₀ value of 6 nM. Imdatifan can be used for the research of various types of diseases including cancer, liver disease, inflammatory disease, pulmonary diseases and iron load disorders .

HY-153016

HIF-2α agonist 2	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
HIF-2α agonist 2 (compound 10) is a *HIF-2α* agonist with an EC₅₀ value of 1.68 μM at the dose of 20 μM. HIF-2α agonist 2 is non-cytotoxic against 786-O-HRE-Luc cells. HIF-2α agonist 2 can be used for oxygen metabolism research .

HY-161265

HIF-2α agonist 3	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
HIF-2α agonist 3 (Compound 14d) is an orally active *HIF-2α* agonist with a EC₅₀ value of 1.78 μM. HIF-2α agonist 3 can be used in the study of renal anemia .

HY-149886

HIF-2α-IN-9	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-9 (compound 35r) is an inhibitor ofHIF-2α. HIF-2α-IN-9 inhibits VEGF-A (IC₅₀=305 nM), and regulates growth-promoting genes in tumor cells, reactivates macrophage-mediated tumor immunity .

HY-139287

M1002 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .

HY-121728

Langkamide	Others	Others
Langkamide is a novel hypoxia-inducible factor-2 (HIF-2) inhibitory pyrrolidone alkaloid isolated from the roots and stems of Piper sarmentosum, which inhibits HIF-2 transcriptional activity with an EC?? value of 14.0μM.

HY-147426

Zifcasiran ADS-007; ARO HIF2	HIF/HIF Prolyl-Hydroxylase	Cancer
Zifcasiran is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran shows antitumor activities and can be used in advanced renal cell carcinoma research ^[2].

HY-147426A

Zifcasiran sodium ADS-007 sodium; ARO HIF2 sodium	HIF/HIF Prolyl-Hydroxylase	Cancer
Zifcasiran sodium is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran sodium shows antitumor activities and can be used in advanced renal cell carcinoma research ^[2].

HY-B2171A

Carubicin hydrochloride Carminomycin hydrochloride; Carminomicin I hydrochloride	Apoptosis	Infection Cancer
Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases ^[2].

HY-B2171

Carubicin Carminomycin; Carminomicin I	Apoptosis	Infection Cancer
Carubicin (Carminomycin) is a microbially-derived compound. Carubicin is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin has the potential for the research of cancer diseases ^[2].

HY-P10223

Cyclo(CRVIIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 65 and 123 μM, respectively .

HY-P10222

Cyclo(CRLLIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 14.5 and 10.2 μM, respectively .

HY-P10221A

Cyclo(CKLIIF) TFA	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 2.6 and 2.2 μM, respectively .

HY-19621

THS-044	HIF/HIF Prolyl-Hydroxylase	Cancer
THS-044 binding stabilizes the HIF2α PAS-B folded state, for regulating HIF2 activity in endogenous and clinical settings.

HY-44809

Izilendustat	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Inflammation/Immunology
Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1) .

HY-44809A

Izilendustat hydrochloride	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology Cancer
Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1) ^[2] .

HY-18371

TC-S 7009	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
TC-S 7009 is a potent and selective *HIF-2α* inhibitor with a K_d of 81 nM. TC-S 7009 is more selective for *HIF-2α* than HIF-1α (K_d ? 5 μM). TC-S 7009 disrupts *HIF-2α* heterodimerization, decreases DNA-binding activity, and reduces *HIF-2α* target gene expression ^[2].

HY-108697

PT2399 5 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
PT2399 is a potent and selective *HIF-2α* antagonist, which directly binds to HIF-2α PAS B domain with an IC₅₀ of 6 nM. PT2399 displays potent antitumor activity in vivo ^[2] .

HY-111547

M1001	HIF/HIF Prolyl-Hydroxylase	Cancer
M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a K_d of 667 nM. M1001 can be used in chronic kidney disease research .

HY-125840

Belzutifan 5+ Cited Publications PT2977; MK-6482	HIF/HIF Prolyl-Hydroxylase	Cancer
Belzutifan (PT2977) is an orally active and selective *HIF-2α* inhibitor with an IC₅₀ of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .

HY-12867

PT-2385 Maximum Cited Publications 41 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
PT-2385 is a selective *HIF-2α* inhibitor with a K_i of less than 50 nM ^[2].

HY-108697A

(Rac)-PT2399	HIF/HIF Prolyl-Hydroxylase	Cancer
(Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a *(HIF-2α)* inhibitor with an IC₅₀ of 0.01 μM .

HY-151341

HIF-1/2α-IN-1	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1/2α-IN-1 is an orally active *HIF-2α* inhibitor. HIF-1/2α-IN-1 inhibits HIF-2α activity with an IC₅₀ value of 0.92 μM. HIF-1/2α-IN-1 also can decrease HIF-1α levels. HIF-1/2α-IN-1 can be used for the research of clear cell renal cell carcinoma (ccRCC) .

HY-113649

AKB-6899	HIF/HIF Prolyl-Hydroxylase	Cancer
AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective *HIF-2α* stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects .

HY-B0219

Allopurinol 5+ Cited Publications	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect ^[2] .

HY-B0219A

Allopurinol sodium 5+ Cited Publications	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol sodium is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol sodium can be used in the research of hyperuricemia and gout. Allopurinol sodium decreases the expression of HIF-1α and HIF-2α protein. Allopurinol sodium shows anti-depressant and anti-nociception activity. Anti-leishmanial effect ^[2] .

HY-B0219R

Allopurinol (Standard)	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol (Standard) is the analytical standard of Allopurinol. This product is intended for research and analytical applications. Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect ^[2] .

HY-120793

CMC2.24 TRB-N0224	Ras Apoptosis MMP	Inflammation/Immunology Cancer
CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC₅₀s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis ^[2] .

Cat. No.	Product Name	Target	Research Area

HY-P10221A

Cyclo(CKLIIF) TFA	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 2.6 and 2.2 μM, respectively .

HY-P10223

Cyclo(CRVIIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 65 and 123 μM, respectively .

HY-P10222

Cyclo(CRLLIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 14.5 and 10.2 μM, respectively .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81700

	HIF2 alpha Antibody (YA1445) bHLHe73; ECYT4; EPAS 1; EPAS1; HIF2A; HLF; MOP 2; PASD2	WB, ICC/IF, FC	Human, Mouse, Rat
	HIF2 alpha Antibody (YA1445) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1445), targeting HIF2 alpha, with a predicted molecular weight of 96 kDa. HIF2 alpha Antibody (YA1445) can be used for WB, ICC/IF, FC experiment in human, mouse, rat background.

HY-P81153

	HIF 2 alpha Antibody Basic helix loop helix PAS protein MOP2; Basic-helix-loop-helix-PAS protein MOP2; bHLHe73; Class E basic helix-loop-helix protein 73; ECYT4; Endothelial PAS domain containing protein 1; Endothelial pas domain protein 1; Endothelial PAS domain-containing protein 1; EPAS 1; EPAS-1; EPAS1; EPAS1_HUMAN; HIF 1 alpha like factor; HIF-1-alpha-like factor; HIF-2-alpha; HIF2-alpha; HIF2A; HLF; Hypoxia inducible factor 2 alpha; Hypoxia inducible factor 2 alpha subunit; Hypoxia-inducible factor 2-alpha; Member of PAS protein 2; Member of pas superfamily 2; MOP 2; MOP2; PAS domain-containing protein 2; PASD2.	WB, IHC-P, FC	Human, Mouse, Rat
	HIF 2 alpha Antibody is an unconjugated, approximately 96 kDa, rabbit-derived, anti-HIF 2 alpha monoclonal antibody. HIF 2 alpha Antibody can be used for:WB, IHC-P, FC expriments in human, mouse, rat background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-147426

Zifcasiran ADS-007; ARO HIF2		siRNAs
Zifcasiran is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran shows antitumor activities and can be used in advanced renal cell carcinoma research ^[2].

HY-147426A

Zifcasiran sodium ADS-007 sodium; ARO HIF2 sodium		siRNAs
Zifcasiran sodium is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran sodium shows antitumor activities and can be used in advanced renal cell carcinoma research ^[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HIF2

Inhibitors & Agonists

Peptides

NaturalProducts

Antibodies

Oligonucleotides

Natural
Products